Bristol-Myers 4Q call likely to focus on new drugs, pending approvals, as patent cliff looms
NEW YORK - Drugmaker Bristol-Myers Squibb Co., which reports its fourth-quarter results before the stock market opens Thursday, likely will focus on how recent and pending approvals of new drugs could help offset a looming revenue plunge as patents on key drugs expire.

2010 FDA Approvals and a Look Ahead
Recent history can help us handicap FDA decisions.